Prince of Wales Clinical School, Faculty of Medicine, the University of New South Wales, Australia; Cancer Research Division, Cancer Council NSW, Australia.
Cancer Research Division, Cancer Council NSW, Australia.
Cancer Epidemiol. 2019 Apr;59:83-103. doi: 10.1016/j.canep.2018.11.008. Epub 2019 Jan 30.
There is currently no national cervical screening or HPV immunization program in Vietnam. This study aims to synthesize available data on the burden of disease and to project the burden of cervical cancer to 2049 if no major interventions are implemented. We reviewed published data sources on risk factors for HPV prevalence, high-grade lesions, cervical cancer incidence and mortality in Vietnam from 1990 to 2017. We then used the available data to project the number of new cervical cancer cases for the period 2013-2049. Data on cervical cancer incidence and mortality in Vietnam are limited; two Vietnamese cancer registries have been reported on by the International Agency for Research on Cancer, which cover urban populations representing ∼20% of the national population. The reported age-standardized cervical cancer incidence in Hanoi was 6.7 (1993-1997), compared to 28.8 and 14.1 per 100,000 women in Ho Chi Minh City (1995-1998 and 2009-2012, respectively). Cancer mortality data are not uniformly available from cancer registries or mortality surveys in Vietnam because cause of death has not been routinely ascertained. Based on available urban population registry data, estimated rates in the rural population, and forward projection of existing trends, we estimate that without any further intervention, the number of new cases will increase from 6930 (range 5671-8493) in 2012 to 8562 (range 5775-12,762) in 2049, giving a total of 379,617 (range 276,879-542,941) new cases over the period 2013-2049. These findings help underpin the case for the delivery of HPV vaccination and cervical screening in Vietnam, and support similar initiatives in other low- and middle-income countries.
越南目前没有全国性的宫颈癌筛查或 HPV 免疫接种计划。本研究旨在综合现有疾病负担数据,并预测如果不实施重大干预措施,到 2049 年宫颈癌的疾病负担。我们回顾了 1990 年至 2017 年越南 HPV 流行率、高级别病变、宫颈癌发病率和死亡率的已发表数据来源。然后,我们利用现有数据预测 2013 年至 2049 年期间新宫颈癌病例的数量。关于越南宫颈癌发病率和死亡率的数据有限;国际癌症研究机构报告了两个越南癌症登记处,它们覆盖了代表全国人口约 20%的城市人口。报告的河内年龄标准化宫颈癌发病率为 6.7(1993-1997 年),而胡志明市分别为 28.8 和 14.1/10 万女性(1995-1998 年和 2009-2012 年)。由于死因未常规确定,越南癌症登记处或死亡率调查的数据并非均匀可用。基于现有城市人口登记处数据、农村人口的估计率和现有趋势的向前预测,我们估计,如果没有进一步的干预,新病例数量将从 2012 年的 6930 例(5671-8493 例)增加到 2049 年的 8562 例(5775-12762 例),在 2013-2049 年期间共新增 379617 例(276879-542941 例)。这些发现有助于支持在越南提供 HPV 疫苗接种和宫颈癌筛查的理由,并支持其他中低收入国家采取类似举措。